SynAct Pharma Logo

SynAct Pharma

Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.

SYNACT | ST

Overview

Corporate Details

ISIN(s):
SE0008241491 (+1 more)
LEI:
549300RRYIEFEQ72N546
Country:
Sweden
Address:
Scheelevägen 2, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SynAct Pharma is a clinical-stage biotechnology company dedicated to developing innovative treatments for inflammatory and autoimmune diseases. The company's core focus is on resolution therapy, an approach designed to resolve ongoing inflammatory processes rather than merely inhibiting them. Its lead compound, resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors to help the body restore immune balance. By targeting the resolution of inflammation, SynAct Pharma aims to reduce disease progression and offer a new standard of care across a wide spectrum of inflammatory conditions, with a key focus on diseases such as rheumatoid arthritis.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 07:45
Share Issue/Capital Change
Förslag till beslut om bemyndigande för styrelsen att besluta om förvärv och öv…
Swedish 55.9 KB
2025-09-29 07:45
Pre-Annual General Meeting Information
Proposal for a resolution on authorization for the Board of Directors to resolv…
English 56.5 KB
2025-09-16 08:45
Board/Management Information
SynAct Pharma’s CFO Björn Westberg leaves for new leading position
English 53.7 KB
2025-09-16 08:45
Board/Management Information
SynAct Pharmas CFO Björn Westberg slutar för ny ledande befattning
Swedish 53.4 KB
2025-08-29 18:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
Swedish 58.9 KB
2025-08-29 18:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in SynAct Pharma AB
English 58.9 KB
2025-08-20 07:30
Interim Report
Swedish 6.6 MB
2025-08-20 07:30
Interim Report
English 6.6 MB
2025-08-15 08:55
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter en andra konvertering av teckningsoptioner
Swedish 62.1 KB
2025-08-15 08:55
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after second conversion of warrants
English 61.3 KB
2025-08-05 11:34
Major Shareholding Notification
Swedish 10.6 KB
2025-07-31 18:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
Swedish 59.6 KB
2025-07-31 18:00
Share Issue/Capital Change
Change in number of shares and votes in SynAct Pharma AB
English 59.3 KB
2025-07-15 22:13
Share Issue/Capital Change
Correction: SynAct to receive SEK 17.7 million after conversion of warrants
English 61.8 KB
2025-07-15 22:13
Share Issue/Capital Change
Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
Swedish 62.8 KB

Automate Your Workflow. Get a real-time feed of all SynAct Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SynAct Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-30 Anders Kronborg Other Buy 28,902 250,002.30 SEK
2024-06-01 Björn Westberg Other Other 516,205 N/A
2024-04-30 Jeppe Øvlesen Other Other 58,139 499,995.40 SEK
2024-04-30 Anders Kronborg Other Other 34,883 299,993.80 SEK
2024-03-21 Jeppe Øvlesen Other Other 245,870 1,696,503.00 SEK
2023-11-09 Thomas Jonassen Other Other 3,531,644 22,072,775.00 SEK
2023-11-09 Thomas Jonass Other Other 2,161,225 13,507,656.25 SEK
2023-01-16 Jeppe Øvlesen Other Other 1,161,777 72,727,240.20 SEK
2023-01-16 James Knight Other Other 77,452 4,848,495.20 SEK
2023-01-16 Thomas Boesen Other Other 32,917 2,060,604.20 SEK

Peer Companies

Company Country Ticker View
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea 214370
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660

Talk to a Data Expert

Have a question? We'll get back to you promptly.